{"id":"W4388182377","doi":"10.1016/j.jacadv.2023.100675","title":"Lipoprotein(a) and Benefit of Antiplatelet Therapy","year":2023,"lang":"en","type":"article","venue":"JACC Advances","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute; St. Jude Medical; CytoSorbents Europe; Silence Therapeutics; Intas Pharmaceuticals; Idorsia Pharmaceuticals; Assistance publique-Hôpitaux de Paris; Daiichi-Sankyo; Zora Biosciences; Belvoir Media Group; Novo Nordisk; MyoKardia; ARCA Biopharma; Regado Biosciences; Medicines Company; AstraZeneca; Amarin Corporation; Ionis Pharmaceuticals; Ironwood Pharmaceuticals, Incorporated; Brigham and Women's Hospital; Boston VA Research Institute; Boston Scientific Corporation; Alnylam Pharmaceuticals; Duke Clinical Research Institute; Eisai; FibroGen; Daiichi Sankyo Europe; Servier; Gilead Sciences; Bristol-Myers Squibb; Cleveland Clinic; HLS Therapeutics; GlaxoSmithKline; Quest Diagnostics; Abbott Laboratories; CSL Behring; Eli Lilly and Company; Moderna; Pfizer; American Heart Association; Intarcia Therapeutics; AstraZeneca Mölndal; Amgen; Abiomed; Sanofi; National Institutes of Health; Regeneron Pharmaceuticals","keywords":"Lipoprotein(a); Medicine; Lipoprotein; Cardiology; Intensive care medicine; Internal medicine; Cholesterol","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001794831,0.0003356551,0.001091531,0.000747386,0.0002599075,0.001628224,0.0002810449,0.001901398,0.003787415],"category_scores_gemma":[0.007597729,0.0002452077,0.0008122558,0.0008667376,0.0003989736,0.0006554635,0.0003614251,0.0020084,0.0005464376],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006005613,"about_ca_system_score_gemma":0.0007981224,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001341628,"about_ca_topic_score_gemma":0.001753675,"domain_scores_codex":[0.9988655,0.0004328167,0.0001445845,0.0001024788,0.0003278872,0.0001267387],"domain_scores_gemma":[0.9953641,0.002389825,0.001155952,0.0002562746,0.0003121693,0.0005216846],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.06573038,0.001783072,0.6594855,0.001528858,0.00887262,0.00195412,0.0002405527,0.002144442,0.006435342,0.01040771,0.01772367,0.2236937],"study_design_scores_gemma":[0.001793127,0.002465896,0.9537129,0.0004419402,0.0041789,0.001790012,0.000238329,0.003006017,0.0008700116,0.01197411,0.01942963,0.0000991553],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.6482033,0.2753749,0.001294711,0.02425326,0.00161814,0.00005289082,0.001894063,0.00009616564,0.04721272],"genre_scores_gemma":[0.9661548,0.0237853,0.0005695979,0.002721176,0.004335397,0.00001670085,0.0007965703,0.00001468479,0.001605814],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003787415,"threshold_uncertainty_score":0.01267022,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01441820122523524,"score_gpt":0.2766879377190152,"score_spread":0.2622697364937799,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}